TNFSF14
Tumor necrosis factor ligand superfamily member 14
As of the edition of 20 October 2026, TNFSF14 (tumor necrosis factor ligand superfamily member 14, UniProt O43557) has 2 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O43557
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 7
- Disease areas
- Immune system; Bones, joints and muscles; Skin and connective tissue; Digestive system; Lungs and airways; Nervous system
- Registered trials of its drugs
- 11
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Baminercept | Stopped | Phase 2 | none listed |
| Quisovalimab | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Avalo Therapeutics | Route A |
| Aevi Genomic Medicine | Route A |
| Biogen | Route A |
The other 0 companies at TNFSF14
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at TNFSF14, ranked, with the facts behind eachRequest access. Nothing is shown until you do.